Penumbra, Inc.
PEN
주식 순위
#1697
Penumbra, Inc., together with its subsidiaries, designs, develops,... Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
주가
$320.95
마지막 동기화: 2026-10-16
시가총액
$12.64B
변동 (1일)
-0.15%
변동 (1년)
28.90%
국가
US
거래 Penumbra, Inc. (PEN)
카테고리
Healthcare
Penumbra, Inc. (PEN)의 영업이익률
October 2026 기준 영업이익률 TTM: 12.45%
Penumbra, Inc.의 최신 재무 보고서와 주가에 따르면 현재 영업이익률 (TTM)은 12.45%입니다. 2023년 말 기준 영업이익률은 6.95%였습니다.
Penumbra, Inc.의 영업이익률 기록 (2012 ~ 2026)
매년 말 영업이익률
| 연도 | 영업이익률 | 변화 |
|---|---|---|
| 2026 (TTM) | 12.45% | 1,496.15% |
| 2024 | 0.78% | -88.78% |
| 2023 | 6.95% | 865.28% |
| 2022 | 0.72% | -172.00% |
| 2021 | -1.00% | -85.61% |
| 2020 | -6.95% | -180.07% |
| 2019 | 8.68% | -4,668.42% |
| 2018 | -0.19% | -154.29% |
| 2017 | 0.35% | -168.63% |
| 2016 | -0.51% | -122.67% |
| 2015 | 2.25% | -6.25% |
| 2014 | 2.40% | -288.98% |
| 2013 | -1.27% | -127.08% |
| 2012 | 4.69% | 0.00% |
유사 기업 또는 경쟁사의 영업이익률
| 회사 | 영업이익률 | 영업이익률 차이 | 국가 |
|---|---|---|---|
| 17.03% | -98.63% |
US
|
|
| 17.86% | -98.57% |
IE
|
|
| 22.03% | -98.23% |
US
|
|
| 21.46% | -98.28% |
US
|
|
| 0.00% | - |
DE
|
회사의 영업이익률이란?
영업이익률은 회사의 수익성을 평가하는 핵심 지표입니다. 높은 영업이익률은 일반적으로 긍정적으로 간주되며, 이는 회사가 제품이나 서비스를 생산 비용보다 훨씬 높은 가격에 판매할 수 있음을 보여줍니다. 영업이익률은 회사의 수익을 매출로 나누어 계산합니다.